Fuyumi Nishihara
Hidaka, 3501298, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Correlation between T cell immunity and the duration of EGFR-TKI resistance acquisition in patients harboring EGFR mutations.
Journal: Cancer immunology, immunotherapy : CII
Published: February 05, 2025
Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1.
Journal: BMC cancer
Published: October 03, 2022
Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy.
Journal: Cancer research
Published: January 12, 2022
Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report.
Journal: Molecular and clinical oncology
Published: March 05, 2021
Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non-small cell lung cancer: Management of adverse events.
Journal: Thoracic cancer
Published: January 24, 2020
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Journal: Thoracic cancer
Published: December 08, 2019
Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Journal: Cancer chemotherapy and pharmacology
Published: November 10, 2019
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
Journal: Cancer immunology research
Published: July 27, 2019
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer.
Journal: Cancer chemotherapy and pharmacology
Published: July 21, 2019
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Journal: Thoracic cancer
Published: January 28, 2019
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
Journal: Thoracic cancer
Published: January 24, 2019
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non-small cell lung cancer patients.
Journal: Thoracic cancer
Published: January 06, 2019
Last Updated: 09/26/2026